Related Experiment Video

Updated: Aug 15, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Targeting CK2 for cancer therapy

Kashif A Ahmad1, Guixia Wang, Joel Slaton

  • 1Cellular and Molecular Biochemistry Research Laboratory, Minneapolis Veterans Affairs Medical Center, Chaska, Minnesota 55417, USA. ahmedk@umn.edu

Anti-Cancer Drugs
|October 14, 2005
PubMed

Insights

Antisense CK2alpha oligodeoxynucleotide (ODN) effectively induces cancer cell apoptosis and tumor resolution. Normal cells show resistance, suggesting a therapeutic window for this novel cancer therapy targeting dysregulated protein kinase CK2.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • Protein kinase CK2 is a ubiquitous enzyme involved in cell growth, proliferation, and apoptosis suppression.
  • CK2 is dysregulated in all examined cancers and exhibits dynamic intracellular shuttling, predominantly in the nucleus of cancer cells.
  • Downregulating CK2 induces apoptosis, suggesting its potential as a cancer therapeutic target.

Purpose of the Study:

  • To investigate the efficacy of antisense CK2alpha oligodeoxynucleotide (ODN) in inducing apoptosis in cancer cells and xenograft models.
  • To assess the therapeutic window of antisense CK2alpha ODN by evaluating its effect on normal versus cancer cells.
  • To explore novel delivery methods for enhancing targeted cancer therapy.

Main Methods:

  • Utilized antisense CK2alpha oligodeoxynucleotide (ODN) in cancer cell cultures and xenograft models (prostate cancer, head and neck squamous cell carcinoma).
  • Assessed dose- and time-dependent effects of ODN on tumor cell death and tumor resolution.
  • Investigated the differential sensitivity of normal and cancer cells to antisense ODN treatment.
  • Explored targeted delivery using sub-50-nm tenascin nanocapsules.

Main Results:

  • Antisense CK2alpha ODN demonstrated potent induction of apoptosis in cancer cells and complete resolution of xenograft tumors at optimal concentrations.
  • Normal and benign cells exhibited relative resistance to antisense CK2alpha ODN treatment, indicating a potential therapeutic window.
  • Novel nanocapsule delivery systems showed promise for targeted cancer cell delivery.

Conclusions:

  • Antisense CK2alpha ODN is a potent inducer of apoptosis in cancer cells, with significant tumor-resolving capabilities.
  • The differential sensitivity between cancer and normal cells suggests a favorable therapeutic window for antisense CK2alpha ODN therapy.
  • Targeted delivery approaches, such as nanocapsules, enhance the specificity and potential efficacy of this cancer therapeutic strategy.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...